<DOC>
	<DOCNO>NCT00240708</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness safety risperidone , formulate long-acting injectable drug , compare risperidone tablet treatment patient schizophrenia .</brief_summary>
	<brief_title>A Study Efficacy Safety Long-acting Injectable Risperidone Risperidone Tablets Patients With Schizophrenia</brief_title>
	<detailed_description>Although many schizophrenia patient currently take oral antipsychotic medication , estimate 75 % difficulty adhere daily oral regimen . Long-acting injectable formulation may eliminate need daily medication enhance patient compliance treatment regimen . This open-label , randomize , Phase III trial patient schizophrenia . One treatment group receive 25 50 mgs long-acting risperidone , formulate intramuscular injection , study initiation 2 week , phase previous antipsychotic medication initial 3 week study . Continuing treatment phase , long-acting injection administer every 2 week Week 24 , post-treatment observation perform 6 week ( total study duration 30 week ) . Patients treatment group take oral risperidone tablet , 2 6 mgs daily , study initiation 24 week . Post-treatment observation continue 1 week group ( total study duration 25 week ) . Assessments effectiveness make specified interval treatment include Positive And Negative Syndrome Scale ( PANSS ) , scale measurement symptom schizophrenia ; Clinical Global Impression - Severity ( CGI-S ) , measure overall severity illness , Clinical Global Impression - Changes ( CGI-C ) ; well , Brief Psychiatric Rating Scale ( BPRS ) . Safety evaluation include incidence adverse event throughout study ; inspection injection site time treatment ; Drug-Induced Extrapyramidal Symptoms Scale ( DIEPSS ) , vital sign ( pulse , blood pressure , temperature ) , laboratory test ( hematology , biochemistry , urinalysis ) monthly interval . The study hypothesis treatment long-acting risperidone injection inferior oral risperidone , measure change PANSS total score baseline endpoint ( 24 week ) , patient schizophrenia generally well-tolerated . Risperidone , long-acting formulation intramuscular injection ( 25 milligram [ mg ] 50mg , maximum ) , give biweekly 24 week . Oral risperidone ( 2mg/day 6mg/day [ maximum ] ) administer daily 24 week .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Diagnosis schizophrenia criterion Diagnostic Statistical Manual Mental Diseases , 4th Edition ( DSMIV ) treatment antipsychotic drug ( 6 milligrams/day risperidone equivalent dose ) 28 day study initiation change dosage Total Positive Negative Syndrome Scale ( PANSS ) score &gt; =60 &lt; 120 start study . Diagnosis mental disease schizophrenia treat sustainedrelease injection antipsychotic medication within 60 day initiation study history cerebrovascular accident , convulsive disorder epilepsy , diabetes mellitus , liver disease , kidney disease , cardiovascular disorder , malignancy physical exhaustion due dehydration malnutrition risk factor diabetes mellitus , hyperglycemia .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>intramuscular injection</keyword>
	<keyword>antipsychotic agent</keyword>
	<keyword>risperidone</keyword>
	<keyword>long-acting injectable</keyword>
</DOC>